Idecabtagene vicleucel

艾基维仑赛

Report date: 2022/07/27 11:05:38

Base Information

Drug NameIdecabtagene vicleucel
Drug Alias NameAnti-BCMA CART cells - bluebird bio/CelgeneAbecmabb-2121
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Blood-derived +[4] 
Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/03/26
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb KkCelgene CorpBristol-Myers Squibb Pharma Eeig
Inactive CompaniesGenetix Biotherapeutics Inc
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeL01XX
Related LinksN/A